Abstract:Abstract To date, two chimeric antigen receptors (CAR)-T cell products from autologous T cells have been approved by The United States Food and Drug Administration (FDA). The case-by-case autologous T cell generation setting is largely considered as a pivotal restraining cause for its large-scale clinical use because of the costly and prolonged manufacturing procedure. Further, activated CAR-T cells mainly express immune checkpoint molecules, including CTLA4, PD1, LAG3, abrogating CAR-T anti-tumor activity. In addition, CAR-T cell therapy potently results in some toxicity, such as cytokine releases syndrome (CRS). Therefore, the development of the universal allogeneic T cells with higher anti-tumor effects is of paramount importance. Thus, genome-editing technologies, in particular, clustered regularly interspaced short palindromic repeat (CRISPR)-Cas9 are currently being used to establish “off-the-shelf” CAR-T cells with robust resistance to immune cell-suppressive molecules. In fact, that simultaneous ablation of PD-1, T cell receptor alpha constant (TRAC or TCR), and also β-2 microglobulin (B2M) by CRISPR-Cas9 technique can support the manufacture of universal CAR-T cells with robust resistance to PD-L1. . Indeed, the ablation of β2M or TARC can severely hinder swift elimination of allogeneic T cells those express foreign HLA-I molecules, and thereby enables the generation of CAR-T cells from allogeneic healthy donors T cells with higher persistence in vivo. Herein, we will deliver a brief overview of the CAR-T cell application in the context of tumor immunotherapy. More importantly, we will discuss recent finding concerning the application of genome editing technologies for preparing universal CAR-T cells or cells that can effectively counter tumor escape, with a special focus on CRISPR-Cas9 technology.

Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies

Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy

Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing

CRISPR/Cas-based CAR-T cells: production and application

Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR/Cas9 gene editing technology

Building Potent Chimeric Antigen Receptor T Cells with CRISPR Genome Editing

Novelty in improvement of CAR T cell-based immunotherapy with the aid of CRISPR system

Applications and Advances of CRISPR-Cas9 in Cancer Immunotherapy

[Advances in Immunotherapy of Hematological Malignancies by Using Chimeric Antigen Receptor-Modified Lymphocytes].

CRISPR, CAR-T, and NK: Current applications and future perspectives

Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy

Therapeutic potential of CRISPR/Cas9 gene editing in engineered T‐cell therapy

CRISPR/Cas9 Gene-Editing in Cancer Immunotherapy: Promoting the Present Revolution in Cancer Therapy and Exploring More

CRISPR/Cas9: A Powerful Strategy to Improve CAR-T Cell Persistence

CRISPR–Cas9 applications in T cells and adoptive T cell therapies

CAR T cells: Building on the CD19 paradigm

The progress of CAR-T therapy in cancer and beyond

Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy